NDA 215515 · Alnylam Pharms INC
Amvuttra
Vutrisiran Sodium · Subcutaneous
NovelOrphanCDER novel approval, Jun 13, 2022: To treat polyneuropathy of hereditary transthyretin-mediated amyloidosis
Last checked: Nov 19, 2026Latest source record: Mar 20, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2022
Jun 13, 2022
Approved uses
2
Original approval plus efficacy supplements
Registered trials
5
4 Phase 3, 1 recruiting
FAERS reports
2,969
2,505 serious, 745 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Nov 6, 2025.
AMVUTTRA is a transthyretin-directed small interfering RNA indicated for the treatment of: the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults ( 1.1 ) the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis in adults to reduce cardiovascular mortality, cardiovascular hospitalizations and urgent heart failure visits ( 1.2 ) 1.1 Polyneuropathy of Hereditary Transthyretin-mediated Amyloidosis AMVUTTRA is indicated for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR-PN) in adults. 1.2 Cardiomyopathy of Wild-type or Hereditary Transthyretin-mediated Amyloidosis AMVUTTRA is indicated for the treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular mortality, cardiovascular hospitalizations and urgent heart failure visits.
Mechanism: Vutrisiran is a double-stranded siRNA-GalNAc conjugate that causes degradation of mutant and wild-type TTR mRNA through RNA interference, which results in a reduction of serum TTR protein and TTR protein deposits in tissues.
Therapeutic areas: Neurology · Rare and genetic disease · Ophthalmology
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Mar 20, 2025 Supplement 6 · Efficacy · priority review OrphanLetterLabelReview
- Jun 13, 2022 Original approval · Type 1 - New Molecular Entity NovelOrphanLabelLetterReview
1 products under this application
- AMVUTTRA · VUTRISIRAN SODIUM EQ 25MG BASE/0.5ML (EQ 25MG BASE/0.5ML) · SOLUTION, SUBCUTANEOUS · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Vutrisiran" as an intervention, any sponsor and status, largest first.
- A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With CardiomyopathyPivotal-lookingEnrolling by invitation
Alnylam PharmaceuticalsAlnylam Pharmaceuticals (ALNY)
NCT06679946 · 700 participants (planned) · Start Dec 3, 2024 · Primary completion Mar 31, 2028
Drug: Vutrisiran · For: Transthyretin Amyloidosis (ATTR) With Cardiomyopathy
Sites: Phoenix, Arizona; Beverly Hills, California; La Jolla, California · 87 sites in all
- HELIOS-B: A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With CardiomyopathyPivotal-lookingActive, not recruiting
Alnylam PharmaceuticalsAlnylam Pharmaceuticals (ALNY)
NCT04153149 · 655 participants · Start Nov 26, 2019 · Primary completion May 8, 2024
Drug: Vutrisiran; Sterile Normal Saline (0.9% NaCl) · For: Transthyretin Amyloidosis (ATTR) With Cardiomyopathy
Sites: La Mesa, California; Los Angeles, California; Stanford, California · 121 sites in all
- HELIOS-A: A Study of Vutrisiran (ALN-TTRSC02) in Patients With Hereditary Transthyretin Amyloidosis (hATTR Amyloidosis)Pivotal-lookingCompleted
Alnylam PharmaceuticalsAlnylam Pharmaceuticals (ALNY)
NCT03759379 · 164 participants · Start Feb 14, 2019 · Primary completion Nov 10, 2020
Drug: Patisiran; Vutrisiran · For: Amyloidosis, Hereditary; Transthyretin Amyloidosis
Sites: La Mesa, California; Aurora, Colorado; Jacksonville, Florida · 64 sites in all
- TRITON-PN: A Study to Evaluate the Efficacy and Safety of Nucresiran in Patients With Hereditary Transthyretin Amyloidosis With PolyneuropathyPivotal-lookingRecruiting
Alnylam PharmaceuticalsAlnylam Pharmaceuticals (ALNY)
NCT07223203 · 125 participants (planned) · Start Feb 3, 2026 · Primary completion Dec 27, 2027
Drug: Nucresiran; Vutrisiran · For: Hereditary Transthyretin-Mediated Amyloidosis With Polyneuropathy; hATTR-PN
Sites: Aurora, Colorado; Chicago, Illinois; Baltimore, Maryland · 61 sites in all
Columbia UniversityAcademic, hospital or other
NCT05635045 · 10 participants · Start Jul 8, 2022 · Primary completion May 7, 2024
Drug: I 124-Evuzamitide · For: Transthyretin Amyloidosis
Sites: New York, New York
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- death601
- hospitalisation367
- intentional dose omission262
- product dose omission issue168
- fall142
- fatigue122
- dyspnoea104
- cardiac failure94
- therapy interrupted94
- gait disturbance87
- arthralgia80
- asthenia80
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2019 | 1 |
| 2021 | 1 |
| 2022 | 21 |
| 2023 | 367 |
| 2024 | 516 |
| 2025 | 868 |
| 2026 | 1,195 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Amvuttra (Vutrisiran Sodium)
2024 spending
$141M
Beneficiaries
409
1,192 claims
Per beneficiary
$344,559
$236,450.75 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $0 |
| 2022 | $11,434,838 |
| 2023 | $67,368,549 |
| 2024 | $140,924,647 |
Part B: Amvuttra (Vutrisiran Sodium) · HCPCS J0225
2024 spending
$229M
Beneficiaries
603
3,103 claims
Per beneficiary
$379,824
2024 ASP limit $4,935.18 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $0 |
| 2022 | $0 |
| 2023 | $167,422,647 |
| 2024 | $229,033,879 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Vutrisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy.
Fontana M, Berk JL, Gillmore JD, et al. · N Engl J Med 2025 · Randomized Controlled Trial, Multicenter Study
- Efficacy and safety of vutrisiran for patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: a randomized clinical trial.
Adams D, Tournev IL, Taylor MS, et al. · Amyloid 2023 · Randomized Controlled Trial
- Impact of vutrisiran on exploratory cardiac parameters in hereditary transthyretin-mediated amyloidosis with polyneuropathy.
Garcia-Pavia P, Grogan M, Kale P, et al. · Eur J Heart Fail 2024 · Randomized Controlled Trial
- Single-Dose Pharmacokinetics and Pharmacodynamics of Transthyretin Targeting N-acetylgalactosamine-Small Interfering Ribonucleic Acid Conjugate, Vutrisiran, in Healthy Subjects.
Habtemariam BA, Karsten V, Attarwala H, et al. · Clin Pharmacol Ther 2021 · Clinical Trial, Phase I, Randomized Controlled Trial
- Impact of Heart Failure Severity on Vutrisiran Efficacy in Transthyretin Amyloidosis With Cardiomyopathy.
Maurer MS, Witteles RM, Garcia-Pavia P, et al. · J Am Coll Cardiol 2025 · Randomized Controlled Trial, Multicenter Study
- Impact of Vutrisiran on Cardiac Biomarkers in Patients With Transthyretin Amyloidosis With Cardiomyopathy From HELIOS-B.
Maurer MS, Berk JL, Damy T, et al. · J Am Coll Cardiol 2025 · Clinical Trial, Phase III, Multicenter Study
Sponsor: Alnylam Pharmaceuticals
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.